Given the centrality of the APC tumour suppressor to CRC, we decided to use a genetic approach in vivo and in vitro to address the differences in Wnt activation by either mutation of β-catenin or mutation of the destruction complex (APC or GSK3). Here, APC is linked to neoplasm.